EUVIMEDEUVIMED entdecken
Crossref

Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms

Jutatip Panaampon, Prin Sungwan, Sawako Fujikawa, Somponnat Sampattavanich, Siwanon Jirawatnotai, Seiji Okada

International Immunopharmacology · 2024-09 · 138 · 112612

DOI: 10.1016/j.intimp.2024.112612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Jutatip Panaampon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan…. Hauptthemen laut MEDLINE: Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Immunological, Bile Duct Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA) is an aggressive and fatal cancer. The prognosis is very poor and no optimal chemotherapy has been established. Human epidermal growth factor receptor 2 (HER2, neu, and erbB2) is highly-expressed in breast cancer and is expressed in many other tumors but poorly expressed in CCA. The anti-HER2 antibody, trastuzumab, has been used for the treatment of HER2-positive breast and gastric cancer. In this study, we examined the surface expression of HER2 on seven Thai liver-fluke-associated CCA cell lines by flow cytometry, and found all of these CCA cells were weakly positive for HER2. MTT assay revealed that trastuzumab directly suppressed the growth of CCA. By using FcR-bearing recombinant Jurkat T-cell-expressing firefly luciferase gene under the control of NFAT response elements, we defined the activities of antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP). ADCC was confirmed by using expanded NK cells. ADCP was confirmed by using mouse peritoneal macrophages and human monocyte-derived macrophages as effector cells. Rabbit serum was administered to test the complement-dependent cytotoxicity (CDC) activity of trastuzumab. Finally, we evaluated the efficacy of trastuzumab in in vivo patient-derived cell xenograft and patient-derived xenograft (PDX) models. Our results showed that a distinct population of CCA (liver-fluke-associated CCA) expressed HER2. Trastuzumab demonstrated a potent inhibitory effect on even HER2 weakly positive CCA both in vitro and in vivo via multiple mechanisms. Thus, HER2 is a promising target in anti-CCA therapy, and trastuzumab can be considered a promising antibody immunotherapy agent for the treatment of CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalBile Duct NeoplasmsCholangiocarcinomaTrastuzumabAnimalsFemaleHumansMaleMiceRabbitsCell Line, TumorJurkat CellsKiller Cells, NaturalPhagocytosisErb-b2 Receptor Tyrosine KinasesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CholangiocarcinomaHER2Patient-derived xenograftTrastuzumab

Substanzen

Antineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan; Division of Hematologic Neoplasia, Department of Medical Oncology, D…
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
  • Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Pharmacology, Faculty of Medicine Siriraj…
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan; Institute of Industrial Nanomaterials, Kumamoto University, 2-39-1 K…

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science

Zitieren

APA

Panaampon, J., Sungwan, P., Fujikawa, S., Sampattavanich, S., Jirawatnotai, S., & Okada, S. (2024). Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms. International Immunopharmacology, 138, 112612. https://doi.org/10.1016/j.intimp.2024.112612

Vancouver

Panaampon J, Sungwan P, Fujikawa S, Sampattavanich S, Jirawatnotai S, Okada S. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms. International Immunopharmacology. 2024;138:112612. doi:10.1016/j.intimp.2024.112612

BibTeX
@article{Panaampon2024,
  author = {Panaampon, Jutatip and Sungwan, Prin and Fujikawa, Sawako and Sampattavanich, Somponnat and Jirawatnotai, Siwanon and Okada, Seiji},
  title = {Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {138},
  pages = {112612},
  doi = {10.1016/j.intimp.2024.112612}
}
Kostenlos starten →